Bayer sells cancer drug to Gruenenthal for up to $431 million
The Wall Street Journal reports that the drug, approved to treat various forms of cancer, is due to lose patent protection in the EU in 2029 and the U.S. in 2030.
TLDR
Bayer is selling a cancer drug to Gruenenthal for up to $431 million, The Wall Street Journal reports. The drug treats various forms of cancer, and its patent protection is due to expire in the EU in 2029 and the U.S. in 2030, according to the newspaper.
Combined views
129.3K
1 Source, first seen 10d ago
likes